Sangamo Therapeutics Inc (SGMO) Stake Increased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lifted its holdings in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 193.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,087 shares of the biopharmaceutical company’s stock after buying an additional 42,917 shares during the period. Cubist Systematic Strategies LLC owned about 0.06% of Sangamo Therapeutics worth $1,237,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of SGMO. Schwab Charles Investment Management Inc. boosted its position in shares of Sangamo Therapeutics by 13.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 433,717 shares of the biopharmaceutical company’s stock worth $7,113,000 after buying an additional 51,801 shares during the period. American Century Companies Inc. boosted its position in shares of Sangamo Therapeutics by 36.8% in the fourth quarter. American Century Companies Inc. now owns 469,099 shares of the biopharmaceutical company’s stock worth $7,693,000 after buying an additional 126,121 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter worth $443,000. California Public Employees Retirement System boosted its position in shares of Sangamo Therapeutics by 30.6% in the fourth quarter. California Public Employees Retirement System now owns 149,235 shares of the biopharmaceutical company’s stock worth $2,447,000 after buying an additional 34,935 shares during the period. Finally, Swiss National Bank boosted its position in shares of Sangamo Therapeutics by 3.9% in the fourth quarter. Swiss National Bank now owns 142,460 shares of the biopharmaceutical company’s stock worth $2,336,000 after buying an additional 5,400 shares during the period. 56.14% of the stock is owned by institutional investors and hedge funds.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 2,278 shares of the firm’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $18.30, for a total transaction of $41,687.40. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Curt A. Herberts III sold 8,163 shares of the firm’s stock in a transaction dated Friday, April 13th. The shares were sold at an average price of $20.00, for a total value of $163,260.00. Following the transaction, the vice president now owns 22,788 shares in the company, valued at $455,760. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,656 shares of company stock valued at $844,303. 1.20% of the stock is owned by corporate insiders.

Shares of NASDAQ:SGMO opened at $16.45 on Wednesday. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 0.14. Sangamo Therapeutics Inc has a 1 year low of $7.35 and a 1 year high of $27.50. The firm has a market cap of $1.59 billion, a P/E ratio of -23.50 and a beta of 2.89.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.52). Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. The firm had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $53.09 million. During the same quarter in the prior year, the business posted ($0.23) earnings per share. Sangamo Therapeutics’s revenue was up 270.6% on a year-over-year basis. analysts anticipate that Sangamo Therapeutics Inc will post -0.59 earnings per share for the current year.

Several analysts recently issued reports on the company. Zacks Investment Research lowered Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, May 16th. ValuEngine lowered Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 8th. BidaskClub lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. Wedbush reiterated a “hold” rating and set a $8.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 13th. Finally, Barclays reiterated a “buy” rating and set a $30.00 price objective on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $21.67.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply